RedHill Biopharma Announces Last Patient Out for Phase 2/3 COV...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
TEL AVIV, Israel and RALEIGH, NC, July 19, 2021, /PRNewswire-AsiaNet/-- Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19 Top-line results expected in the coming weeksOpaganib, a novel, dual antiviral and anti-inflammatory investigational COVID-19 pill,...
Authors: LATEST ASIANET NEWS RELEASES